1. RODNA
  2. CONICET
  3. CONICET
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.provenanceCONICET-
dc.creatorMizenina, Olga-
dc.creatorHsu, Mayla-
dc.creatorJean Pierre, Ninochka-
dc.creatorAravantinou, Meropi-
dc.creatorLevendosky, Keith-
dc.creatorPaglini, Maria Gabriela-
dc.creatorZydowsky, Thomas M.-
dc.creatorRobbiani, Melissa-
dc.creatorFernández Romero, José A.-
dc.date2018-11-06T19:29:20Z-
dc.date2018-11-06T19:29:20Z-
dc.date2017-12-15-
dc.date2018-10-22T15:53:59Z-
dc.date.accessioned2019-04-29T15:30:06Z-
dc.date.available2019-04-29T15:30:06Z-
dc.date.issued2017-12-15-
dc.identifierMizenina, Olga; Hsu, Mayla; Jean Pierre, Ninochka; Aravantinou, Meropi; Levendosky, Keith; et al.; MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1; Springer; Drug Delivery and Translational Research; 7; 6; 15-12-2017; 859-866-
dc.identifier2190-3948-
dc.identifierhttp://hdl.handle.net/11336/63812-
dc.identifierCONICET Digital-
dc.identifierCONICET-
dc.identifier.urihttp://rodna.bn.gov.ar:8080/jspui/handle/bnmm/295281-
dc.descriptionWe previously showed that the combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 with zinc acetate (ZA) formulated in a carrageenan (CG; MZC) gel provided macaques significant protection against vaginal simian-human immunodeficiency virus-RT (SHIV-RT) challenge, better than either MIV-150/CG or ZA/CG. The MZC gel was shown to be safe in a phase 1 clinical trial. Herein, we used in vitro approaches to study the antiviral properties of ZA and the MIV-150/ZA combination, compared to other NNRTIs. Like other NNRTIs, MIV-150 has EC50 values in the subnanomolar to nanomolar range against wild type and NNRTI or RT-resistant HIVs. While less potent than NNRTIs, ZA was shown to be active in primary cells against laboratory-adapted and primary HIV-1 isolates and HIV-1 isolates/clones with NNRTI and RT resistance mutations, with EC50 values between 20 and 110 μM. The MIV-150/ZA combination had a potent and broad antiviral activity in primary cells. In vitro resistance selection studies revealed that previously described NNRTI-resistant mutations were selected by MIV-150. ZA-resistant virus retained susceptibility to MIV-150 (and other RTIs) and MIV-150-selected virus remained sensitive to ZA. Notably, resistant virus was not selected when cultured in the presence of both ZA and MIV-150. This underscores the potency and breadth of the MIV-150/ZA combination, supporting preclinical macaque studies and the advancement of MZC microbicides into clinical testing.-
dc.descriptionFil: Mizenina, Olga. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Hsu, Mayla. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Jean Pierre, Ninochka. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Aravantinou, Meropi. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Levendosky, Keith. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Paglini, Maria Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología "Dr. J. M. Vanella"; Argentina-
dc.descriptionFil: Zydowsky, Thomas M.. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Robbiani, Melissa. Center for Biomedical Research; Estados Unidos-
dc.descriptionFil: Fernández Romero, José A.. Center for Biomedical Research; Estados Unidos. The City University of New York; Estados Unidos-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.languageeng-
dc.publisherSpringer-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s13346-017-0421-4-
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1007/s13346-017-0421-4-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/-
dc.sourcereponame:CONICET Digital (CONICET)-
dc.sourceinstname:Consejo Nacional de Investigaciones Científicas y Técnicas-
dc.sourceinstacron:CONICET-
dc.source.urihttp://hdl.handle.net/11336/63812-
dc.subjectANTIVIRAL-
dc.subjectHIV-1-
dc.subjectMICROBICIDES-
dc.subjectNNRTIS-
dc.subjectZINC-
dc.subjectSalud Ocupacional-
dc.subjectCiencias de la Salud-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.titleMIV-150 and zinc acetate combination provides potent and broad activity against HIV-1-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.typeinfo:ar-repo/semantics/articulo-
Aparece en las colecciones: CONICET

Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro sencillo del ítem